

PERSONAL INFORMATION

Wilhelmus Petrus Johannes (Wim) Witjes

WORK EXPERIENCE

- June 1984-September 1985 **MD, 1st Lieutenant Dutch Army**
Military Hospital (Netherlands)
Training in Surgery and Orthopedics
- November 1985-March 1987 **MD**
St. Elisabeth Hospital, Amersfoort (Netherlands)
Training in Surgery
- June 1987-April 1990 **MD**
Canisius Wilhelmina Hospital, Nijmegen (Netherlands)
Training in Surgery and Urology
- April 1990-February 1997 **MD, Head Clinical Research Department of Dept. of Urology**
University Hospital Nijmegen (Netherlands)
Training in Clinical Research, Statistics and Epidemiology
- February 1997-November 2000 **Managing Director**
Intertrial B.V. (Netherlands)
Setting up and conducting Clinical Research
- April 1990- Present **MD, PhD, Clinical Research Director**
Radboud University Medical Centre (Netherlands)
Contract negotiating, conducting clinical trials within the department of urology.
- November 2000- Present **Scientific and Clinical Research Director**
CuraTrial B.V. (Netherlands)
Setting up and conducting clinical trials and registries at the European Association of Urology Research Foundation

EDUCATION AND TRAINING

- August 1976-June 1984 **University training MD**
Katholic University Nijmegen (Netherlands)
MD
- June 1984-May 1997 **PhD**
University Hospital Nijmegen (Netherlands)
PhD thesis 'micturation variables in the assessment and treatment of patients with lower urinary tract symptoms'.
- October 1991- Present **GCP expertise**
various GCP training courses attended / given as teacher (Netherlands)
GCP certified
GCP teacher

ADDITIONAL INFORMATION

Expertise

oncological urology / uro-oncology

GCP

methodology of clinical trials and registries

cancer

clinical trials

urology

health care

design of registries and post marketing follow-up registries

Publications

1. Witjes WPJ, Vollaard EJ, Crul BJP, Helsper PE: Postoperative treatment of pain by sublingual "on demand" administration of buprenorphine in combination with naproxen or paracetamol. In: Topics in Clinical Pharmacy, Delporte JP, Moes A & Shafford A (eds) Uitg: European Society on Clinical Pharmacy, Uithoorn: 319-323, 1989.
2. Witjes WPJ, Vollaard EJ, Crul BJP, Limpens C: Sublingual buprenorphine obviates the need for parenteral morphine in cholecystectomy patients. In: Progress in Clinical Pharmacy: Rational Use of Drugs, Muller NF & Hekster YA, (eds) Uitg: European Society on Clinical Pharmacy, Den Haag: 292, 1989.
3. Witjes WPJ, Crul BJP, Vollaard EJ, Joosten HJM, van Egmond J: Application of sublingual buprenorphine in combination with naproxen or paracetamol for postoperative pain relief in cholecystectomy patients in a double blind study. Acta Anesthesiol Scand 36(4): 323-327, 1992.
4. Witjes WPJ, van der Meijden APM, Roos EPM, Witjes JA, Steerenberg PA, Doesburg W, Debruyne FMJ: BCG-RIVM versus BCG-Tice versus Mitomycin-C in superficial bladder cancer. Rationale, design and interim analysis of the trial of the South-East Cooperative Urological Group, The Netherlands. In: Progr Clin Biol Res; Volume 378, EORTC GU Group Monograph 11: Recent Progress in Bladder and Kidney Cancer. Fritz H Schröder (Ed.) Wiley-Liss, New York: 59-67, 1992.
5. Witjes WPJ, Meuleman EJH, Lycklama à Nijeholt GAB, van Driel MF, Leliefeld HHJ, Kropman RF, Doesburg WH: The efficacy and acceptance of autoinjection therapy with the combination of papaverine/phenolamine in patients with chronic erectile dysfunction. A prospective multicentre trial in 60 patients. Int J Impotence Res 4(2) 65-72, 1992.
6. Witjes WPJ, Horenblas S, Oosterhof GON, Schaafsma HE, Debruyne FMJ: Neo-adjuvant therapy in prostate cancer - Is it of any use ? Eur Urol 24(4): 433-437, 1993.
7. Witjes WPJ, Oosterhof GON, Schaafsma HE, Debruyne FMJ: The value of neoadjuvant therapy in localized prostate cancer. Int J of Urology: official journal of the Japanese Urological Association 2(1): 1-5, 1995.
8. Witjes WPJ, Oosterhof GON, Schaafsma HE, Debruyne FMJ: Current status of neoadjuvant therapy in localized prostate cancer. The Prostate 27(6): 297-303, 1995. DOI: 10.1002/pros.2990270602.
9. Witjes WPJ, Horenblas S, Oosterhof GON, Schaafsma HE, Debruyne FMJ: What is the role of neo-adjuvant therapy in prostatic carcinoma ? [Qual e il ruolo della terapia neoadiuvante nel carcinoma prostatico ?] Minerva Urol Nefrol 47(4): 209-214, 1995.
10. Witjes WPJ, Witjes JA, Oosterhof GON, Debruyne FMJ on behalf of the Dutch South-East Cooperative Urological Group: Update on the Dutch cooperative trial: Mitomycin-C versus BCG-Tice versus BCG-RIVM in the treatment of patients with pTa-pT1 papillary carcinoma and carcinoma in situ of the urinary bladder. Seminars in Urologic Oncology 14 (1 suppl. 1): 10-17, 1996.
11. Witjes WPJ, Rosier PFWM, de Wildt MJAM, van Iersel MP, Debruyne FMJ, de la Rosette JJMCH: Urodynamic and clinical effects of terazosin therapy in symptomatic patients with benign

- prostatic hyperplasia. *J Urol* 155(4): 1317-1323, 1996. DOI: 10.1016/S0022-5347(01)66255-4.
12. Witjes WPJ, de Wildt MJAM, Rosier PFWM, Caris CTM, Debruyne FMJ, de la Rosette JJMCH: Variability of clinical and pressure-flow study variables after 6 months of watchful waiting in patients with lower urinary tract symptoms and benign prostatic enlargement. *J Urol* 156(3): 1026-1034, 1996. DOI: 10.1016/S0022-5347(01)65692-1.
13. Witjes WPJ: Clinical trial management in het ziekenhuis. In: J.M.A. Penders (ed): Clinical trial management in het ziekenhuis. Boerhave commissie voor Postacademisch Onderwijs in Geneeskunde, Rijks-universiteit Leiden. ISBN 90-6767-319-6. pp 31-41, 1996.
14. Witjes WPJ, Schulman CC, Debruyne FMJ for the European study group on neoadjuvant treatment of prostate cancer: Preliminary results of a prospective randomized study comparing radical prostatectomy versus radical prostatectomy associated with neoadjuvant hormonal combination therapy in T2-3 N0 M0 prostatic carcinoma. *Urology*, 49(3A): 65-69, 1997. DOI: 10.1016/S0090-4295(97)00171-4.
15. Witjes WPJ, Rosier PFWM, Caris CTM, Debruyne FMJ, de la Rosette JJMCH: Urodynamic and clinical effects of terazosin therapy in symptomatic patients with and without bladder outlet obstruction. A stratified analysis. *Urology* 49(2): 197-205, 1997. DOI: 10.1016/S0090-4295(96)00490-6.
16. Witjes WPJ, Rosier PFWM, Caris CTM, Debruyne FMJ, de la Rosette JJMCH: Urodynamic and clinical effects of terazosin therapy in symptomatic patients with and without bladder outlet obstruction. A stratified analysis. Reply. *Urology* 49: 206-206, 1997.
17. Witjes WPJ, de la Rosette JJMCH, Donovan JL, Peters TJ, Abrams P, Kay HE, Höfner K, Kinn A-C, Walter S and the ICS-BPH' study group: The ICS-BPH' Study: International differences in lower urinary tract symptoms and related bother. *J Urol* 157(4): 1295-1300, 1997. DOI: 10.1016/S0022-5347(01)64955-3.
18. Witjes WPJ, Robertson A, Rosier PFWM, Neal DE, Debruyne FMJ, de la Rosette JJMCH: Urodynamic and clinical effects of non-invasive and minimally invasive treatments in elderly males with lower urinary tract symptoms stratified according to the grade of obstruction. *Urology* 50(1): 55-61, 1997. DOI: 10.1016/S0090-4295(97)00112-X.
19. Witjes WPJ, Aarnink RG, Ezz-El-Din K, Wijkstra H, Debruyne FMJ, de la Rosette JJMCH: The correlation between prostate volume, transition zone volume, transition zone index and clinical and urodynamic investigations in patients with symptomatic benign prostatic hyperplasia. *Brit J Urol* 80(1): 84-91, 1997. DOI: 10.1046/j.1464-410X.1997.00252.x.
20. Witjes WPJ, de la Rosette JJMCH, de Vette JAJ: Diagnostiek en behandeling van patiënten met benigne prostaathyperplasie. Colofon, Van Zuiden Communications, Alphen a/d Rijn. ISBN 90-75141-34-3, 1997.
21. Witjes WPJ, Wijkstra H, Debruyne FMJ, de la Rosette JJMCH: Quantitative assessment of uroflow: Is there a circadian rhythm? *Urology* 50(2): 221-228, 1997. DOI: 10.1046/j.1464-410X.1997.00252.x.
22. Witjes WPJ: Micturition variables in the assessment and treatment of patients with lower urinary tract symptoms. Proefschrift. Benda drukkers, Nijmegen. ISBN 90-90103-90-2, 1997.
23. Witjes WPJ, Fernández del Moral P, Debruyne FMJ por el Grupo cooperativo europeo para el tratamiento neoadyuvante del cáncer de próstata: Tratamiento hormonal neoadyuvante en pacientes con carcinoma prostático localizado (estadio T2-3, N0, M0). Primeros resultados de un estudio europeo. In: Estrategia actual para el futuro de la Uro-Oncología. H. Villavicencio, E. Solsona (Eds). ISBN 84-88336-31-4. Accion Medica, Madrid, 1997, pp 145-154.
24. Witjes WPJ: Mictievariabelen bij de diagnostiek en de behandeling van patiënten met lagere urinewegsymptomen. *Ned Tijdschr v Urologie* 3: 72-76, 1997.
25. Witjes WPJ, de la Rosette JJMCH, Zerbib M, Vignoli GC, Geffroy C, Debruyne FMJ, Wijkstra H: Computerized artifact correction of uroflow-curves: Towards a more consistent quantitative assessment of maximum flow. *European Urology* 33(1): 54-63, 1998. DOI: 10.1159/000019533.
26. Witjes WPJ: Adjuvant and neoadjuvant treatment of prostate cancer. Symposium report of an ESU organized symposium in cooperation with the Hungarian Urological Association "Prostate cancer, Epidemiology, prevention and endocrine treatment". Budapest, October 1997. The ESU

International Symposium series (ISSN 1461-8621) 1: 33-37, 1998.

27. Witjes WPJ, Schulman CC, Debruyne FMJ and the European study group on neoadjuvant treatment of prostate cancer: Results of a European randomized study comparing radical prostatectomy and radical prostatectomy plus neoadjuvant hormonal combination therapy in stage T2-3N0M0 prostatic carcinoma. *Mol Urol* 2(3): 181-185, 1998.
28. Witjes WPJ, König M, Boeminghaus FP, Hall RR, Schulman CC, Zurlo M, Fittipaldo A, Riggi M, Debruyne FMJ for the European Bropirime Study Group: Results of a European comparative randomized study comparing oral bropirime versus intravesical BCG treatment in BCG-naive patients with carcinoma in situ of the urinary bladder. *Eur Urol* 36: 576-581, 1999. DOI: 10.1159/000020051.
29. Witjes WPJ: De spelers in het veld van het klinische geneesmiddelen onderzoek. *De Urograaf* 12 (4) 15-17, 2001.
30. Witjes WPJ, de la Rosette JJMCH, van den Berg-Segers A, Colongo D, Koch G, Zlotta AR, Colau A, de Wildt MJAM, Wijkstra H: Computerised assessment of maximum uroflow: an efficient, consistent and valid approach. *European Urology* 41 (2): 206-213, 2002. DOI: 10.1016/S0302-2838(01)00037-9.
31. Witjes WPJ: Clinical Research Directions in Urinary Incontinence. *Clinical Researcher* 2 (4): 16-19, 2002. Remedica Publishing London.
32. Witjes WPJ: EU-richtlijn klinisch geneesmiddelen onderzoek 2001/20/EG. *De Urograaf* 14 (2): 25-27, 2003.
33. Witjes WPJ: Editorial Comment on: The Correlation between Metabolic Syndrome and Prostatic Growth in Patients with Benign Prostatic Hyperplasia. Ozden C, Ozdal OL, Urgancioglu G, Koyuncu H, Gokkaya S, Memis A. *European Urology* 2007 Jan; 51(1): 199-206.
34. Witjes WPJ: The European Association of Urology Central Research Office. A new player enters the field of European basic and clinical urological research. *International Clinical Trials* p 65, May 2010.
35. Witjes WPJ, Lammers RJM, Hendricksen K, Caris CTM, Janzing-Pastors MHC, Witjes JA: Is roken een risicofactor voor recidieven na transurethrale resectie van niet-spieerinvassief blaascarcinoom? *Spreekuur Urologie* 2 (2), 2011.
36. Witjes WPJ, Patel A, Wirth M. ZEUS, the quest for the Holy Grail of prostate cancer bone metastases prevention continues. *Eur. Urol.* 67: 492-495, 2015. DOI: 10.1016/j.eururo.2014.03.009. <http://www.ncbi.nlm.nih.gov/pubmed/24726855>
37. Witjes WPJ: Re: DNA-repair defects and Olaparib in Metastatic Prostate Cancer. Mateo J, Carreira S, Sandhu S, et al. *N. Engl J Med* 2015; 373(18) 1697-1708. Contribution Words of Wisdom to *Eur. Urol*, 70 (2016) 204-5, 2016. Accepted. DOI: 10.1016/j.eururo.2016.03.059.
38. Crul BJP, Witjes WPJ, Vollaard EJ, Joos-ten HJM, van Egmond J: Sublinguale toedie-ning van buprenorfine in combinatie met na-proxen of paracetamol als pijnstilling bij patiënten na galblaasopera-tie - een dubbelblind onder-zoek. *Ned Tijdschr v Anesthe-si-ol* 5: 173-178, 1992.
39. Fernandez del Moral P, Witjes WPJ: Prostaatcarcinoom; Algemeen medische informa-tie. *Ned Tijdschr Tandheelkd* 99: 131-133, 1992.
40. Debruyne FMJ, Witjes WPJ: Overview of current status of Total Androgen Depriva-ti-on in Metastasized Prostate Cancer. *Eur Urol* 24: (suppl. 2) 67-71, 1993.
41. Debruyne FMJ and Witjes WPJ: Overview of the current status of total androgen depriva-ti-on in metastasized prostate cancer. *World J Urol* 11(4): 233-236, 1993.
42. Debruyne FMJ und Witjes WPJ: Uebersicht über den derzeitigen Stand der totalen Androgen-blockade bei meta-stasierendem Prosta-takarzinom. *Niere Blase Prostata aktuell* 4: 73-80, 1993.
43. Debruyne FMJ, Witjes WPJ, Schulman CC, van Cangh PJ, Ooster-hof GON and The Euro-pean Study Group on Neoadjuvant Treat-ment: A multicentre trial of combined neoadjuvant androgen block-ade with Zoladex and Flutamide prior to radical prostatec-tomy in prostate cancer. *Eur Urol* 26 (suppl.1): 4, 1994.
44. van Gils-Gielen RJM, Witjes WPJ, Caris CTM, De-bruy-ne FMJ, Witjes JA, Oos-terhof GON and members of the Dutch South East Coop-erative Urological Group: Risk factors in carcinoma in

- situ of the urinary bladder. *Urology* 45(4): 581-586, 1995. DOI: 10.1016/S0090-4295(99)80047-8.
45. van Iersel MP, Witjes WPJ, de la Rosette JJMCH, Oosterhof GON: Prostate specific antigen density: correlation with histological diagnosis of prostate cancer, benign prostatic hyperplasia and prostatitis. *Brit J Urol* 76(1): 47-53, 1995.
46. Schulman CC, Witjes WPJ, Van Cangh PJ, et al: Downstaging of localized prostate cancer by combination therapy: the European randomized trial. *International Symposium on Recent Advances in Diagnosis and Treatment of Prostate Cancer*, Quebec City, September 21-23, p 22, 1995.
47. d'Hollosy W, Witjes WPJ, Mars NJI, de Vries Robbé PF, Debruyne FMJ, Wijkstra H: Knowledge-based support in study design of scientific urological research. *Proc. IEEE-EMBS: 17th Ann Int Conf of Engineering in Medicine and Biology Society*, Montréal, 1995, pp 697-698.
48. de la Rosette JJMCH, Witjes WPJ, Debruyne FMJ, Kersten P, Wijkstra H: Improved reliability of uroflowmetry investigations: results of a portable home-based uroflowmetry study. *Brit J Urol* 78(3): 385-390, 1996. DOI: 10.1046/j.1464-410X.1996.00115.x.
49. Debruyne FMJ, Witjes WPJ, Fitzpatrick J, Kirby R, Kirk D, Prezioso D for the ITT Group: The International Terazosin Trial (ITT): A multicentre study of the long-term efficacy and safety of terazosin in the treatment of benign prostatic hyperplasia. *Eur Urol* 30(3): 369-376, 1996.
50. van Iersel MP, Witjes WPJ, Thomas CMG, Segers MFG, Oosterhof GON, Debruyne FMJ: Review on the simultaneous determination of total prostate specific antigen and free prostate specific antigen. *The Prostate (suppl.)* 7: 48-57, 1996.
51. Schulman CC, Witjes WPJ, Zlotta AR, Debruyne FMJ for the European group on neoadjuvant treatment of prostate cancer: Neoadjuvant combined androgen deprivation therapy in locally confined prostatic carcinoma. Preliminary results of a European randomized study. *Mol Urol* 1: 221-225, 1997.
52. de la Rosette JJMCH, Witjes WPJ, Schäfer W, Abrams P, Donovan JL, Peters TJ, Millard RJ, Fridodt-Miller C, Kalomiris P and the ICS-BPH study group: Relationships between lower urinary tract symptoms and bladder outlet obstruction: results from the ICS-BPH study. *Neurourol Urodynam* 17(2): 99-108, 1998. DOI: 10.1002/(SICI)1520-6777(1998)17:2<99::AID-NAU3>3.0.CO;2-7.
53. Debruyne FMJ, Witjes WPJ: Neoadjuvant hormonal treatment in localized prostate cancer: a critical appraisal. In: Kaisary AV, Griffiths K, Denis L, Murphy GP (eds): *Textbook of prostate cancer: Pathology, Diagnosis and Treatment*. Martin Dunitz Ltd, London. ISBN: 1-85317-422-X. pp 249-260, 1999.
54. Debruyne FMJ, Witjes WPJ: Neoadjuvant hormonal therapy prior to radical prostatectomy: The European experience. *Mol. Urol* 4 (3): 251-257, 2000.
55. Hendricksen K, Witjes WPJ, Idema JG, Kums JJM, van Vierssen Trip OB, de Bruin MJFM, Vergunst H, Caris CTM, Janzing Pastors MHD, Witjes JA: Comparison of three schedules of intravesical epirubicin in patients with non muscle invasive bladder cancer. *Eur Urol* 53: 984-991, 2008. DOI: 10.1016/j.eururo.2007.12.033.
56. Heidenreich A, Witjes W, Bjerklund-Johansson T-E, Patel A for the EAU Research Foundation: Therapies used in prostate cancer patients by European urologists: data on indication, with a focus on expectations, perceived barriers and guideline compliance related to the use of bisphosphonates. *Urol Int* 89: 30-38, 2012. DOI: 10.1159/000338810. <http://www.ncbi.nlm.nih.gov/pubmed/22699678>
57. Lammers RJM, Witjes WPJ, Hendricksen K, Caris CTM, Janzing-Pastors MHC, Witjes JA: Smoking status is a risk factor for recurrence after transurethral resection of nonmuscle-invasive bladder cancer. *Eur Urol*. 2011 Oct;60(4):713-20. doi: 10.1016/j.eururo.2011.07.010. Epub 2011 Jul 14. PMID: 21794974.
58. Lammers RJM, Witjes WPJ, Janzing-Pastors MHC, Caris CTM, Witjes JA: Intracutaneous and intravesical Immunotherapy with Keyhole Limpet Hemocyanin is inferior to intravesical Mitomycin-C in preventing recurrences in patients with non-muscle-invasive bladder cancer: Results from a prospective randomized phase III trial. *J Clin Oncology* 30(18): 2273-2279, 2012. DOI: 10.1200/JCO.2011.39.2936.
59. Dijkstra S, Witjes WPJ, Roos EPM, Vijverberg PLM, Geboers ADH, Bruins JL, Smits GAHJ, Vergunst H, Mulders PFA: The AVOCAT study: Bicalutamide monotherapy versus combined

- bicalutamide plus dutasteride therapy for patients with locally advanced or metastatic carcinoma of the prostate a long term follow-up comparison and quality of life analysis. SpringerPlus (2016) 5: 653. DOI 10.1186/s40064-016-2280-8.
60. Lammers RJM: Risk management and treatment of non-muscle invasive bladder cancer. Doctoral Thesis. Defence: Nijmegen June 30, 2015. Promotor Witjes JA, Copromotor Witjes WPJ. ISBN/EAN 978-94-6259-686-3.
61. Debruyne FMJ, Oosterhof GON, Witjes WPJ: Neo adjuvante (inductie-ve) chemotherapie bij blaascarcinoom: een kritische analyse. In: Recente ontwikkelingen in de behandeling van prostaat-hyperplasie, prostaat-kanker en blaaskanker. FH Schröder (Ed) Uitg: Medicom: 87-96, 1991.
62. Witjes JA, van de Meijden APM, Witjes WPJ, Doesburg W, Schaafsma HE, Debruyne FMJ and the members of the Dutch South-East Cooperative Urological Group: A randomised prospective study comparing intravesical instillations of Mitomycin-C, BCG-Tice, and BCG-RIVM in pTa-pT1 tumors and primary carcinoma in situ of the urinary bladder. Eur J Cancer 29A(12): 1672-1676, 1993. DOI: 10.1016/0959-8049(93)90102-L.
63. de Mulder PHM, Punt CJA, Witjes WPJ, Debruyne FMJ: Therapie mit Zytokinen beim fortgeschrittenen Nierenzellkarzinom. In: Rübber H, Goepel M, Schmitz-Dräger BJ (eds): Immuntherapie in der Uroonkologie. Springer-Verlag, Berlin, Heidelberg, New York, pp 273-282, 1993.
64. d'Hollosy W, Hendriks BTh, Witjes WPJ, Debruyne FMJ, Wijkstra H: Improvement of data management in scientific urological research. Proc. IEEE 16th Ann Int Conf in Med and Biol 2: 1394-1395, Baltimore, November 3-6, 1994, pp 1394-1395.
65. Vegt PDJ, Witjes JA, Witjes WPJ, Doesburg WH, Debruyne FMJ, van der Meijden APM: A randomized study of intravesical Mitomycin-C, BCG-Tice and BCG-RIVM treatment in pTa-pT1 papillary carcinoma and carcinoma in situ of the bladder. J Urol 153(3): 929-933, 1995. DOI: 10.1016/S0022-5347(01)67606-7.
66. van Iersel MP, Thomas CMG, Witjes WPJ, de Graaf R, de la Rosette JJMCH, Debruyne FMJ: Clinical implications of the rise and fall of PSA after laser prostatectomy. Brit J Urol 78(5): 742-746, 1996. DOI: 10.1046/j.1464-410X.1996.21914.x.
67. Selli C, Travaglini F, Witjes WPJ for the European Study Group on Neo-Adjuvant Treatment of Prostatic Cancer: Neoadjuvant therapy in patients with prostatic carcinoma. J Chemother 8, 4 (suppl) : 320-322, 1996.
68. Burger M, Mulders P, Witjes W: Use of neoadjuvant chemotherapy for muscle invasive bladder cancer is low among major European centres: results of a feasibility questionnaire. European Urology 61 (5): 1070-1071, 2012. DOI: 10.1016/j.eururo.2012.01.039. <http://www.ncbi.nlm.nih.gov/pubmed/22336379>
69. D'Ancona FCH, Francisca EAE, Witjes WPJ, Welling L, Debruyne FMJ, de la Rosette JJMCH: High energy thermotherapy versus transurethral resection in the treatment of benign prostatic hyperplasia: Results of a prospective randomized study with 1 year of follow up. J Urol 158(1): 120-125, 1997. DOI: 10.1097/00005392-199707000-00035.
70. D'Ancona FCH, Francisca EAE, Witjes WPJ, Welling L, Debruyne FMJ, de la Rosette JJMCH: Transurethral resection of the prostate versus high-energy thermotherapy of the prostate in patients with benign prostatic hyperplasia: long term results. Brit J Urol 81(2): 259-264, 1998.
71. Björk T, Schalken J, Witjes W, Ljungberg B, Lilja H: Similar rates of exponential decrease in serum concentrations of free prostate-specific antigen (PSA), PSA complexed to Alpha-1-antichymotrypsin, and human glandular kallikrein 2 (hK2) in prostate cancer patients treated with GnRH Analogues. Prostate 47: 14-20, 2001.
72. Niall F. Davis, G.S. Jack, W.P. Witjes, A. Bjartell, C. Caris, A. Patel, A. de la Taille, N. Lawrentschuk, D.M. Bolton, A. Tubaro: Medical therapy versus transurethral resection of the prostate (TURP) for the treatment of symptomatic benign prostatic enlargement (BPE): a cost minimisation analysis. World J Urol Accepted aug 2018. <https://doi.org/10.1007/s00345-018-2454-9>
73. Crul BJP, Vollaard EJ, Helsper PE, Witjes WPJ, Limpens C: Sublinguale "on demand" toediening van buprenorfine in combinatie met naproxen of paracetamol geeft goede pijnstilling bij

laparotomieën. Ned Tijdschr v Anesthesiol 2; 1: 16-19, 1989.

74. van Iersel MP, Thomas CMG, Segers MFG, Witjes WPJ, Debruyne FMJ, Oosterhof GON: The use of 'ultrasensitive' prostate-specific antigen assays in the detection of biochemical recurrence after radical prostatectomy. *Brit J Urol* 77(3): 418-422, 1996. DOI: 10.1046/j.1464-410X.1996.91017.x.

75. Debruyne FMJ, Dijkman GA, Lee DCH and Witjes WPJ on behalf of the Dutch South East Cooperative Urological Group: A new long-acting formulation of the LHRH analogue, goserelin: results of studies in prostate cancer. *J Urol* 155(4): 1352-1354, 1996. DOI: 10.1016/S0022-5347(01)66264-5.

76. Fernandez del Moral P, Dijkman GA, Debruyne FMJ, Witjes WPJ, Kolvenbag GJCM for the Dutch South East Cooperative Urological Group: Three-month depot of goserelin acetate: clinical efficacy and endocrine profile. *Urology* 48(6): 894-900, 1996. DOI: 10.1016/S0090-4295(96)00300-7.

77. d'Hollosy W, de Vries Robbé PF, Mars NJL, Witjes WPJ, Debruyne FMJ, Wijkstra H: Representation of domain knowledge needed to define relevant study variables for clinical trials in urology. Paper 532. Proc. 18th Annual International Conference IEEE Engineering in Medicine and Biology Society, Amsterdam, 31 oktober 1996, pp 2012-2013.

78. Buzelin JM, Fonteyne E, Kontturi M, Witjes WPJ, Khan A: Comparison of tamsulosin with alfuzosin in the treatment of patients with lower urinary tract symptoms suggestive of bladder outlet obstruction (symptomatic benign prostatic hyperplasia). *Brit J Urol* 80(4): 597-605, 1997. DOI: 10.1046/j.1464-410X.1997.00205.x.

79. Erratum: Buzelin JM, Fonteyne E, Kontturi M, Witjes WPJ, Khan A: Comparison of tamsulosin with alfuzosin in the treatment of patients with lower urinary tract symptoms suggestive of bladder outlet obstruction (symptomatic benign prostatic hyperplasia). *Brit J Urol* 81: 510, 1998.

80. Sonke GS, Robertson C, Verbeek ALM, Witjes WPJ, de la Rosette JJMCH, Kiemeny LALM: A method for estimating within-patient variability in maximal urinary flow rate adjusted for voided volume. *Urology* 59: 368-372, 2002. DOI: 10.1016/S0090-4295(01)01547-3.

81. Debruyne FMJ, Jardin A, Colloï D, Resel L, Witjes WPJ, Delauche-Cavallier MC, McCarthy C, Geffriaud-Ricouard C for the European ALFIN study group: SR-alfuzosin, finasteride and the combination of both in the treatment of benign prostatic hyperplasia. *Eur Urol* 34(3): 169-175, 1998. DOI: 10.1159/000019706.

82. Lammers RJM, Palou J, Witjes WPJ, Janzing-Pastors MHD, Caris CTM and Witjes JA: Comparison of expected treatment outcome provided by risk models and international guidelines with observed treatment outcome in a cohort of Dutch non-muscle-invasive bladder cancer patients treated with intravesical chemotherapy. *BJU Int* 114(2): 193-201, 2014. doi: 10.1111/bju.12495. <http://www.ncbi.nlm.nih.gov/pubmed/24304638>

83. Lammers RJM, Hendriks JCM, Palou J, Witjes WPJ and Witjes JA: Prediction model for recurrence probabilities after intravesical chemotherapy in patients with non-muscle-invasive bladder cancer, including external validation. *World J Urol*. 2016 Feb; 34(2):173-80. DOI: 10.1007/s00345-015-1598-0, 05/2015. <http://www.ncbi.nlm.nih.gov/pubmed/26025189>

84. Witjes JA, Caris CTM, Mungan NA, Debruyne FMJ, Witjes WPJ: Results of a randomized phase III trial of sequential intravesical therapy with Mitomycin-C and bacillus Calmette-Guérin versus Mitomycin-C alone in patients with superficial bladder cancer. *J Urol* 160(5): 1668-1672, 1998. DOI: 10.1016/S0022-5347(01)62377-2.

85. Re (multiple letters): Witjes JA, Caris CTM, Mungan NA, Debruyne FMJ, Witjes WPJ, Morales A: Results of a randomized phase III trial of sequential intravesical therapy with Mitomycin-C and bacillus Calmette-Guérin versus Mitomycin-C alone in patients with superficial bladder cancer. *J Urol* 161: 1582-1583, 1999.

86. Schneider D, Bianchini G, Horgan D, Michiels S, Witjes W, Plun-Favreau J, Brand A, and Lawler M. on behalf of EAPM Working Group for Oncology Clinical Research: Establishing the Evidence Bar for Molecular Diagnostics in Personalised Cancer Care. *Public Health Genomics* (Karger) pp 1-10, 2015. DOI: 10.1159/000441556. <http://www.ncbi.nlm.nih.gov/pubmed/26571110>

87. Schulman CC, Debruyne FMJ, Forster G, Selvaggi FP, Zlotta AR and Witjes WPJ for the European Study Group on Neo-adjuvant Treatment of Prostate Cancer: 4-Year follow up results of a European prospective randomized study on neoadjuvant hormonal combination therapy prior to radical prostatectomy in T2 -T3 N0 M0 prostate cancer. *Eur Urol* 38(6): 706-713, 2000. DOI: 10.1159/000020366.
88. Witjes JA, van de Meijden APM, Collette L, Sylvester R, Debruyne FMJ, van Aubel A, Witjes WPJ, and the EORTC GU Group and the Dutch South East Cooperative Urological Group: Long-term follow up of an EORTC randomized prospective trial comparing intravesical bacille Calmette-Guérin-RIVM and Mitomycin C in superficial bladder cancer. *Urology* 52(3): 403-410, 1998. DOI: 10.1016/S0090-4295(98)00212-X.
89. Kamat AM, Li R, ODonnell MA, Black PC, Roupert M, Catto JW, Comperat E, Ingersoll MA, Witjes WP, McConkey DJ, Witjes JA: Predicting Response to Intravesical Bacillus Calmette-Guérin Immunotherapy: Are We There Yet? A Systematic Review. *Euro Urol* published on line, November 2017.
90. van Andel G, Fernandez del Moral P, Caris CTM, Carpentier P, Wils J, de Bruin MJFM, Witjes JA, Debruyne FMJ, Witjes WPJ: A randomized study comparing epirubicin in a 4-weekly versus a weekly intravenous regimen in patients with metastatic, hormone resistant prostatic carcinoma: effects on health related quality of life. *World J Urol* 21(3): 177-182, 2003. DOI: 10.1016/S0090-4295(01)01547-3.
91. Wirth M, Tammela T, Cicalese V, Gomez Veiga F, Delaere K, Miller K, Tubaro A, Schulze M, Debruyne F, Huland H, Patel A, Lecouvet F, Caris C, Witjes W: Can zoledronic acid prevent bone metastases in high-risk non-metastatic prostate cancer patients ? Efficacy and safety results of the Zometa European Study (ZEUS). A prospective, randomized, open-label, multi-national study of the European Association of Urology (EAU) in co-operation with the Scandinavian Prostate Cancer Group (SPCG) and the Arbeitsgemeinschaft für Urologische Onkologie (AUO). *Eur Urol.* 67: 482-491, 2015. DOI: 10.1016/j.eururo.2014.02.014. <http://www.ncbi.nlm.nih.gov/pubmed/24630685>
92. Colombel M, Heidenreich A, Martínez-Piñero L, Babjuk M, Korneyev I, Surcel C, Yakovlev P, Colombo R, Radziszewski P, Witjes F, Mulders P, Schipper R, Witjes W.P.J.: Peri-operative Chemotherapy in Muscle Invasive Bladder Cancer: Overview and the unmet clinical need for an alternative adjuvant therapy as studied in the MAGNOLIA clinical trial. *Eur Urol.* 2014 Mar;65(3):509-11.
doi: 10.1016/j.eururo.2013.10.056. Epub 2013 Nov 11.
<http://www.ncbi.nlm.nih.gov/pubmed/24268503>
93. ..., .., .., .., .., .., M. Colombel, A. Heidenreich, L. Martínez-Piñero, M. Babjuk, C. Surcel, P. Yakovlev, R. Colombo, P. Radziszewski, F. Witjes, P. Mulders, R. Schipper, W. Witjes: : . MAGNOLIA. 4:73-76, 2013.
94. Mariana Reza, Mattias Ohlsson, Manfred Wirth, Teuvo Tammela, Virgilio Cicalese, Francisco Gomez Veiga, Kurt Miller, Andrea Tubaro, Frans Debruyne, Anup Patel, Christien Caris, Wim Witjes, Ola Thorsson, Per Wollmer, Lars Edenbrandt, Elin Trägårdh, Anders Bjartell: Bone Scan Index as a new imaging biomarker for quantitative evaluation of treatment effects on bone metastases: An explorative side study based on the Zeus/SPCG11 study. *European Journal of Nuclear Medicine and Molecular Imaging* Volume: 43 Pages: S341 Published: OCT 2016.
95. Mulders PFA, Martínez-Piñero L, Heidenreich A, Babjuk M, Colombel M, Colombo R, Radziszewski P, Korneyev I, Surcel C, Yakovlev P, Witjes J.A, Caris C, Schipper R, Witjes W.P.J. on behalf of the MAGNOLIA Study Group of the EAU Research Foundation: Adjuvant recMAGE-A3 immunotherapy after cystectomy for Muscle-Invasive Bladder Cancer: Lessons learned from the Phase II Clinical Trial MAGNOLIA. *Eur. Urol. Focus* 5 (5): 849-852, 2019.
<https://doi.org/10.1016/j.euf.2018.02.005> <https://www.ncbi.nlm.nih.gov/pubmed/29477797>
96. Liselotte M.S. Boevé, Maarten C.C.M. Hulshof, André N. Vis, Aeilko H. Zwinderman, Jos W.R. Twisk, Wim P.J. Witjes, Karl P.J. Delaere, R. Jeroen A. van Moorselaar, Paul C.M.S. Verhagen, George van Andel: The Effect on Survival of Androgen Deprivation Therapy Combined with Concurrent Radiation Therapy to the Prostate Compared to Androgen Deprivation Therapy Alone in Patients with Primary Bone Metastatic Prostate Cancer in a Prospective Randomized Clinical Trial:

Data from the HORRAD Trial. Published online. Eur. Urol. Sept. 2018.

<https://doi.org/10.1016/j.eururo.2018.09.008>

97. Kasivisvanathan V, Rannikko AS, Borghi M, Panebianco V, Mynderse LA, Vaarala MH, Briganti A, Budäus L, Hellawell G, Hindley RG, Roobol MJ, Eggener S, Ghei M, Villers A, Bladou F, Villeirs GM, Virdi J, Boxler S, Robert G, Singh PB, Venderink W, Hadaschik BA, Ruffion A, Hu JC, Margolis D, Crouzet S, Klotz L, Taneja SS, Pinto P, Gill I, Allen C, Giganti F, Freeman A, Morris S, Punwani S, Williams NR, Brew-Graves C, Deeks J, Takwoingi Y, Emberton M, Moore CM; PRECISION Study Group Collaborators*

MRI-Targeted or Standard Biopsy for Prostate-Cancer Diagnosis. N Engl J Med. 2018 May

10;378(19):1767-1777. doi: 10.1056/NEJMoa1801993. Epub 2018 Mar 18.

*Collaborators (96): Kenttämies A, Mirtti T, Becher EF, Catalano C, Grompone M, Del Monte M, Costantino L, Sciarra A, DEramo G, Salvo V, Campa R, King BF, Froemming AT, McLaren RH, Draayer PJ, Smith JE, Doty KJ, Tonttila P, Virta V, Kuisma M, Pääkkö E, Hirvikoski P, Montorsi F, Stabile A, De Cobelli F, Esposito A, Picozzi M, Cristel G, Brembilla G, Hung M, Ocampo F, Otieno M, Ramachandran N, Pendse D, Kirkham A, Jameson C, Ratynska M, Ben-Salha I, Leyh-Bannurah SR, Beyersdorff D, Sauter G, Chambers A, Pathmanathan B, Gayed W, Vrentzou E, Baldwin R, Rajkumar G, Emara A, Nedas T, Edwards A, Bangma CH, Busstra MB, Schoots IG, Oto A, Gerber G, Shah T, Hamid S, Erotocritou P, Maraj B, Kumaradeevan J, Puech P, Olivier J, Loutochin O, De Visschere P, Lumen N, Praet M, Arya M, Thoeny H, Michiels C, Lebras Y, Smith G, Grant L, Goode A, El Sheikh S, Fütterer JJ, Sedelaar JPM, Radtke JP, Hohenfellner M, Bonekamp D, Schlemmer HP, Rouvière O, Magill P, Elkin D, Jichi F, Simon R, Patel S, Potyka I, McCartan N, Baldini C, Grierson J, Haider A, Caris C, van Egmond J, Witjes W, Mulders P, Bjartell A.

<https://www.ncbi.nlm.nih.gov/pubmed/29552975>

98. Mariana Reza, Manfred Wirth, Teuvo Tammela, Virgilio Cicalese, Francisco Gomez Veiga, Peter Mulders, Kurt Miller, Andrea Tubaro, Frans Debruyne, Anup Patel, Christien Caris, Wim Witjes, Ola Thorsson, Per Wollmer, Lars Edenbrandt, Mattias Ohlsson, Anders S Bjartell: Automated Bone Scan Index (aBSI) as an imaging biomarker to predict overall survival in the Zometa European Study/SPCG11 (ZEUS). Accepted in Eur. Urol. Oncology, May 2019.

doi: 10.1016/j.euo.2019.05.002. [Epub ahead of print]. PMID: 31186177

<https://pubmed.ncbi.nlm.nih.gov/31186177>

99. Sachin Malde, Anup Patel, Luis Martnez-Pineiro, Alexandre de la Taille, Anders Bjartell, Andrea Tubaro, Wim Witjes, Christien Caris: Incidence of Nocturia in Men with Lower Urinary Tract Symptoms Associated with Benign Prostatic Enlargement and Outcomes After Medical Treatment: Results from the Evolution European Association of Urology Research Foundation Prospective Multinational Registry. European Urology Focus. Published online July 2019:

<https://doi.org/10.1016/j.euf.2019.07.003>.

100. Liselotte M.S. Boevé, Maarten C.C.M. Hulshof, André N. Vis, Peter de Vries, R. Jeroen A. van Moorselaar, Wim P.J. Witjes, Karl P.J. Delaere, R. Paul C.M.S. Verhagen, George van Andel: Lokale behandeling bij het primair gemetastaseerd prostaatacarcinoom. Local therapy in primary metastatic prostate cancer.

Published online: September 2019 DOI: 10.1007/s13629-019-00263-w. Tijdschr. Urol. (Oct. 2019) 9:103-107.

101. Liselotte M.S. Boevé, Maarten C.C.M. Hulshof, Paul C.M.S. Verhagen, Jos W.R. Twisk, Wim P.J. Witjes, Peter de Vries, R. Jeroen A. van Moorselaar, George van Andel, André N. Vis: Patient-reported Quality of Life in Patients with Primary Metastatic Prostate Cancer Treated with Androgen Deprivation Therapy with and without Concurrent Radiation Therapy to the Prostate in a Prospective Randomised Clinical Trial. Data from the HORRAD Trial. Accepted EU Aug 2020.

<https://doi.org/10.1016/j.eururo.2020.08.023>

102. Nikita R. Bhatt, Niall F. Davis, W.P. Witjes, A. Bjartell, C. Caris, A. Patel, A. de la Taille, A. Tubaro: Quality of life with pharmacological treatment in patients with benign prostatic enlargement: Results from the Evolution European prospective multicenter multi-national Registry Study. Accepted WJU April 2020. DOI: 10.1007/s00345-020-03219-7.

<https://pubmed.ncbi.nlm.nih.gov/32367157/>

103. Tubaro A, Speakman M, de la Taille A, Martínez-Piñero L, Berges R, Patel A, Bjartell A, Caris C, Witjes W: A European registry evaluating symptomatic effectiveness of pharmacologically treated patients with LUTS due to benign prostatic enlargement (BPE): the lessons learned. Accepted to Journal of Urology, October 2020.
104. Marc-Oliver Grimm, Antoine G. van der Heijden, Marc Colombel, Tim Muilwijk, Luis Martínez-Piñero, Marko M. Babjuk, Levent N. Türkeri, Joan Palou, Anup Pateli, Anders S. Bjartell, Christien Caris, Raymond G. Schipper, Wim P.J. Witjes for the EAU Research Foundation NIMBUS Study Group: Treatment of High-Grade Non-Muscle Invasive Bladder Carcinoma by Standard Number and Dose of BCG Instillations versus Reduced Number and Standard Dose of BCG Instillations. Results of the European Association of Urology Research Foundation Randomised Phase III Clinical Trial NIMBUS. European Urology 78 (2020) 690-698.
<https://doi.org/10.1016/j.eururo.2020.04.066>
105. Marc-Oliver Grimm, Christien Caris, Wim P.J. Witjes for the NIMBUS Study Group: Reply to Emre Karabay and Ilker Tnays Letter to the Editor.
 Re: Nonmuscle-invasive Bladder Carcinoma by Standard Number and Dose of BCG Instillations Versus Reduced Number and Standard Dose of BCG Instillations: Results of the European Association of Urology Research Foundation Randomised Phase III Clinical Trial NIMBUS. Eur. Urol. 78 (4) E163-E164, Oct, 2020. <https://doi.org/10.1016/j.eururo.2020.07.004>
106. Wim Witjes: EAU RF Studies on devices, instruments, disposables, etc. The MDR and why post-marketing clinical follow-up studies are needed. European Urology Today.Vol. 32 (2) pp13,14, March May 2020.
107. Nikita R. Bhatt, Niall F.Davis, W.P. Witjes, A. Bjartell, C. Caris, A. Patel, A. de la Taille, M. Speakman, L. Martínez-Piñero, A. Tubaro: "Contemporary use of phytotherapy in patients with Lower Urinary Tract Symptoms due to Benign Prostatic Hyperplasia- results from the EVOLUTION European Registry. Accepted for publication WJU, October 2020.
<https://doi.org/10.1007/s00345-020-03219-7>

Projects For past projects see publications
 For current projects see <http://uroweb.org/research/projects/>

Memberships Dutch Urological Association (DUA; NVU)
 European Association of Urology (EAU)
 Association of CROs in the Netherlands (ACRON)
 Board of the EAU Research Foundation (EAU RF)

Other Relevant Information